Alnylam's Givlaari Gets Approval In Europe For Rare Disease
Zacks Investment Research | Mar 03, 2020 09:22PM ET
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) announced that the European Commission has approved Givlaari (givosiran) for the treatment of acute hepatic porphyria (AHP) in patients aged 12 years or older. The drug will be available as subcutaneous injection. The approval in Europe was expected as the drug had received positive recommendation from the Committee for Medicinal Products for Human Use of the European Medicines Agency in January 2020.
The ultra-rare AHP disease can lead to severe abdominal pain, vomiting and seizures, which can be life-threatening due to the possibility of paralysis and respiratory arrest during attacks.
The approval was based on impressive data from the phase III ENVISION study, which showed that treatment with Givlaari resulted in 74% reduction in the rate of porphyria attacks. The drug is the first and only therapy approved in Europe, which demonstrated prevention of AHP attacks, reduction in chronic pain and improving quality of life.
Please note that Givlaari was approved by the FDA in November last year for the same indication. It has already been launched in the United States and generated $0.2 million in the fourth quarter of 2019. The drug is priced at $575,000 per annum in the U.S. market.
Shares of the company have rallied 31.1% year to date against the industry ’s decrease of 7.7%.
Alnylam is focused on development of novel RNAi-based therapeutics targeting primarily rare-disease indications. The company has several collaborations with leading pharmaceutical and life sciences companies including Novartis (NYSE:NVS) , Roche (OTC:RHHBY) and Ionis Pharmaceuticals (NASDAQ:IONS) among others. It has received approval for two RNAi-based therapeutics — Givlaari and Onpattro — in the United States and Europe in the last 18 months.
Onpattro was approved in 2018 for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. The drug generated $166 million in 2019. Apart from its approved drugs, Alnylam is developing several RNAi-based candidates. The company has initiated new drug application (“NDA”) rolling submission for lumasiran, with remaining sections expected to be submitted to the FDA in early 2020. The NDA is seeking approval for lumasiran as a treatment for primary hyperoxaluria type I, a rare-disorder affecting kidneys.
Further, the company expects to advance inclisiran, being evaluated to treat hypercholesterolemia, along with partner Novartis and filed an NDA in December 2019. It is also developing another candidate, fitusiran, in collaboration with Sanofi (PA:SASY) in late-stage study as a treatment for hemophilia A or B.
Get The News You Want
Alnylam Pharmaceuticals, Inc. Price
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.